FDA Decision on Dupilumab for COPD Pushed Back to September 2024
FDA has no concerns about the "approvability" of dupilumab for the new indication but needs additional time to review phase 3 data it requested early in May.
COVID-19 Infection in Second Trimester Raises Risk of Preeclampsia: Daily Dose
Your daily dose of the clinical news you may have missed.
Primary Care Needs Training on Menopausal Issues, Treatment Options, says Women's Midlife Health Expert
Primary care clinicians are essential to maximizing evidence-based midlife care for women, according to Professor of Obstetrics & Gynecology JoAnn Pinkerton, MD.
Semaglutide Explored for Treatment of Alcohol, Nicotine Use Disorders
Findings from 2 early stage studies reported at a recent clinical meeting support the safety and tolerability of the GLP-1RA in persons with substance use disorders.
Premenstrual Disorders May Increase Suicide Risk, Especially Among Young Women, Study Warns
The risk of mortality was not higher for women with vs without PMD overall but was particularly elevated for young women and for suicide across age of PMD diagnosis.
Elinzanetant Outcomes from the OASIS 1 and 2 Phase 3 Trials: A Read Out with Lead Investigator JoAnn Pinkerton, MD
The novel dual neurokinin-1,3 antagonist reduced VMS after just 1 week of treatment, Pinkerton said, and improved sleep and quality of life, as well. Hear more.
Women's Preventive Services Guideline: 7 Questions
These 7 questions are based on the most recent update to the guidelines by the Women's Preventive Services Initiative, including supporting resources.
Plozasiran, an Investigational RNAi Therapy, Reduces Triglyceride Levels in Adults with Mixed Hyperlipidemia
Plozasiran, in the phase 2b MUIR trial, significantly reduced triglyceride and triglyceride rich lipoprotein levels through targeted action against APOC3.
Tezepelumab Found to Reduce Rate of COPD Exacerbations in Persons with Wide Range of Blood Eosinophil Levels: Daily Dose
Racial Disparities Persist in Respiratory Disease Research, Diagnostics: Expert Panel Discussion at 2024 ATS
Pulmonology experts agreed that adopting race-neutral diagnostic and research practices could help mitigate a range of inequities faced by minority populations.
Semaglutide Significantly Reduces Risk of Renal Events, MACE, Mortality in People with CKD, T2D in Final FLOW Trial Findings
The pluripotent GLP-1 mimetic reduced risk for renal disease endpoints by 24% and MACE by 18% plus significantly retarded decline in eGFR vs placebo, study authors reported.
Ultraprocessed Foods Raise Risk for Cardiometabolic Issues in Children, According to New Research
Findings underscore a need for public health initiatives to educate vulnerable populations on cardiometabolic risks, researchers report.
GLP-1RAs Linked to Lower Risk for Cirrhosis in Patients with MASLD, Type 2 Diabetes: Daily Dose
Cannabis: An "Ins and Outs" Primer for Primary Care
A concise update on legal status, FDA approvals, patient safety, and public perception.
Once-a-Week Insulin Matches Daily Insulin in Lowering HbA1c: Daily Dose
US Drug Overdose Deaths Declined in 2023 for the First Time in 5 Years, CDC Reports
The 3% decline in 2023 compared with 2022 is "heartening news," CDC's Houry says, but the mission is far from accomplished.
Blood-Based Test May be Effective Option for Colorectal Cancer Screening in Average-Risk Adults
DDW 2024. An investigational blood-based screening test demonstrated nearly a 80% sensitivity for detecting CRC, according to a large prospective study.
Find and Treat Asthma and COPD: All Interventions Make a Difference, Study Concludes
Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.
Drug Use in the US: Best and Worst States in 2024
Which state has the lowest percentage of teen drug users? Or the highest percentage of adults with unmet drug-treatment needs? Answers from a new report, here.
Higher Prepregnancy BMI Category Linked to Increase in Poor Maternal and Neonatal Outcomes
Women with class 3 obesity before becoming pregnant have up to a 4.5-fold greater risk of composite maternal morbidity that includes preeclampsia, preterm delivery, DM.
